Novartis

Swiss pharmaceutical giant Novartis debuted a mobile phone app on Wednesday designed to collect real-time data from participants in ophthalmology clinical trials. The FocalView app, created using Apple's ResearchKit, aims to improve understanding of eye disease progression by enabling ...

(CNBC); GSK Consumer Healthcare appoints Rahul Kapoor as EVP- HR (Business Line); Novartis files for Japanese approval of Kymriah (The Pharma Letter); Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ...

Good morning. I have a treat for you today. Two of the most insightful investors I know—Venrock partners Bryan Roberts and Bob Kocher—are giving Brainstorm Health Daily readers a sneak peek at their 2018 Health Prognosis, which is compiled from their survey of 300 savvy insiders in the field. You can ...

Novartis and Pear Therapeutics are partnering again, this time in a go-to-market deal focused on two prescription-only digital therapeutics for drug abuse. Novartis' Sandoz unit will take on sales and marketing for reSET and reSET-O, putting together a field sales team and detailing the products to doctors.

Lastly, Novartis has provided some comments on the dilution on 2018 EPS for the recent disposal of the stake in the OTC JV with GlaxoSmithKline (NYSE:GSK) and for the acquisition of Avexis (NASDAQ:AVXS). These moves will have a dilutive impact on 2018 EPS of around $0.20, thus a 3% dilution ...

In the latest company move to embrace all things digital, Novartis has launched an app that it hopes will boost participation in its ophthalmology trials. The pharma giant is calling the tech FocalView, and it'll be used by researchers to track disease progression in patients with ophthalmic disease real-time.

Novartis' Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the ...

A corruption prosecutor investigating the Novartis bribery case ordered on Tuesday the opening of ten bank accounts and disclosure of other assets belonging to the prominent politicians named in the case file. In a document sent to Greek banks and the Hellenic Capital Market Commission, Eleni ...

Novartis sued a former executive last summer after she left the Swiss drugmaker to join Cambridge-based Biogen as head of U.S. sales and marketing, accusing her of using a USB drive to steal trade secrets on her way out the door. The lawsuit, which has not been previously reported, stems from Biogen's ...

Karande left Novartis to take a vice president role at Intarcia, where he was also the general manager for the company's ITCA 650 product, a temperature-stable form of exenatide delivered by a matchstick-sized pump implanted just beneath the skin. He left Intarcia in March, just a month after the company ...

This week saw the headline-grabbing multi-billion dollar sell-off by Novartis of its consumer healthcare business. Reflecting the Swiss entity's desire to focus resources on strengthening its position in higher-priority therapeutic spaces, the deal provides funds that are likely to be used for acquisitions of ...

The intellectual property in question, known as patent '688, covers a vector for expression of a polypeptide in a mammalian cell, and was ultimately used in the development of Novartis' Lucentis. The Swiss pharma contends that to produce Eylea and Zaltrap, Regeneron tapped a commercial gene ...

Novartis Pharma, the Switzerland-based pharmaceuticals manufacturer is strengthening its focus on digitalisation and data. With the company's focus in these two areas already making an impact in the last 2-3 years, Hyderabad operations are all set to contribute to its global operations in data analytics ...

Now the Boston/Bay Area-based biotech will work with Joris van Dam, the executive director for digital therapeutics at the Novartis Institutes for BioMedical Research, on interactive digital programs for schizophrenia and multiple sclerosis. Getting a heavyweight player in the biopharma industry to ...

It's far from the first time Novartis has tapped tech partners to further its goals for prescription drugs. Among its deals is a team-up with Qualcomm aimed at using the wireless giant's connected devices and in-home collection stations to monitor patients in clinical studies, and they're developing a smart ...

early a dozen advocacy groups began a series of protests against Novartis this week for using “lies, threats and bribes” to pressure developing countries not to pursue measures to widen access to medicines. The groups are targeting Novartis because the drug maker figures prominently in an intensifying ...

Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It's the first time a pharma company has made a development deal with a digital therapeutic, according to Pear. “We have been in ...

Spencer Fisk jumped to Rubius just a few days ago, joining what seems to be a steady migration out of Novartis' cell and gene therapy operation. He was the global head of Cell and Gene Technical Development and Manufacturing. Fisk took the place of Karen Walker, who left for Seattle Genetics last ...

Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company ...

China upstart EpimAb Biotherapeutics has wooed in a top researcher from Novartis as its first chief medical officer. Bin Peng, who had been global chief of oncology translational medicine at NIBR's Shanghai group, is jumping to the startup, which grabbed a $25 million launch round last April and is allied ...

In an unexpected twist to the bribery probe Novartis faces in Greece, the Swiss pharma's Athens headquarters was vandalized by anarchists. About 30 people launched the assault at around 5 a.m. Sunday local time, smashed windows and splashed red paint at the building, according to local police report ...

Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market. The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the ...

Swiss pharmaceuticals company Novartis will move toward making a decision on the fate of Alcon — its eye care business — in the first half of 2019, its chief executive officer reiterated on Sunday. "With Alcon ... we look forward to taking a potential action, moving toward a potential decision in the first half of ...